METHOD FOR PREDICTING CLINICAL EFFECTIVENESS OF CLIMACTERIC SYNDROME MELATONIN IN FEMALES IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN Russian patent published in 2020 - IPC A61B5/00 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gynaecology. For prediction of clinical effectiveness of climacteric syndrome melatonin in females in perimenopause and postmenopause, climacteric syndrome severity is assessed; determining on an empty stomach follicle-stimulating hormone, luteinizing hormone, oestradiol; determining metabolite 6-sulphatoxymelatonin in two portions of urine, wherein taking an evening portion of urine is carried out from 22.00 to 24.00 hours, and morning from 05.00 to 08.00 hours; detecting melatonin secretion deficiency by means of melatonin deficiency test questionnaire; use of the WHQ questionnaire for women's health. Additionally, the absence or presence of menopause is determined, the weight of the woman is determined, the following scales are used from the WHQ questionnaire of women's health: depression, somatic symptoms, memory/attention, vasomotor symptoms, anxiety/fear, sexual disorders, sleeping problems, attractiveness. Based on the obtained data, calculating an F index indicating a predicted clinical effectiveness in melatonin 3 mg/day, which is determined by an original mathematical formula. If F is less than 6.72, positive clinical effectiveness is predicted, and if F is more than 6.72, no clinical effectiveness is predicted.

EFFECT: method provides higher accuracy, effectiveness and timeliness of predicting melatonin intake 3 mg/day before administration to a woman, which improves efficiency of therapeutic and rehabilitation measures.

1 cl, 3 ex